Immunotherapy can revolutionize anti-cancer therapy if specific targets are available.
INTRODUCTION
Immunotherapy is currently transforming clinical oncology and holds promise for cure even for patients with metastatic disease (Mellman et al., 2011; Chen J J Immunol Res 2017) . The success of many immunotherapeutic approaches, e.g. adoptive T cell therapy, largely depends on the availability of specific immunogenic target structures presented via Major Histocompatibility Complexes (MHCs) on the surface of cancer cells, but not on that of normal tissues (Coulie et al., 2014) . Genetically instable and hyper-mutated cancer entities such as malignant melanoma and lung carcinoma offer such highly specific target structures through missense mutations in the protein coding genome that generate 'neo-antigens' (Schumacher and Schreiber, 2015) .
However, many cancer types such as pediatric cancers are characterized by a remarkably stable and oligo-mutated genome (Lawrence et al., 2013) . In addition, the few recurrent somatic mutations found in pediatric cancers are hardly immunogenic (Orentas et al., 2012) .
Thus, specific immunotherapy of oligo-mutated cancers is challenging, but may be enabled by the expression of non-mutated cancer-specific genes (CSGs) (Coulie et al., 2014) .
Many CSGs are only expressed during early embryogenesis or in immune-privileged germline tissues such as testis (Monk and Holding, 2001; Simpson et al., 2005) . This restricted expression pattern increases the likelihood of circulating lymphocytes directed against immunogenic peptides encoded by these CSGs (Simpson et al., 2005) , which can be exploited clinically. In neuroblastoma and Ewing sarcoma, which are aggressive and oligomutated pediatric cancers (Pugh et al., 2013; Tirode et al., 2014) , adoptive T cell therapy targeting CSGs has been successfully applied in humanized mouse models Kirschner et al., 2017; Schirmer et al., 2016; Singh et al., 2016 ) and a first set of patients (Thiel et al., 2017) . Screening for additional CSGs could be enabled by comprehensive and already available transcriptome datasets of cancer and normal tissues (Rung and Brazma, 2013) , However, due to the lack of specific algorithms and user-friendly tools, the identification of CSGs and derivative peptides with high affinity to MHCs continues to be laborious and slow (Gubin et al., 2015) .
To accelerate this process and to identify CSGs suitable for targeting various oligo-mutated cancer entities, we developed an algorithm and provide an intuitive software termed RAVEN (Rich Analysis of Variable gene Expressions in Numerous tissues), which automatizes the systematic and fast identification of cancer-specific peptides with high affinity to MHCs starting from gene expression data. By applying RAVEN to a dataset of more than 2,700 gene expression microarrays comprising 50 tumor entities and 71 normal tissue types, we identified a library of peptides suitable for targeting multiple cancers. Our datasets and software represent a rich resource for the development of immunotherapies.
MATERIALS AND METHODS

Microarray data
Publicly available gene expression data generated with Affymetrix HG-U133Plus2.0 microarrays for 3,101 samples comprising 50 tumor entities and 71 normal tissue were retrieved from the Gene Expression Omnibus (GEO) or the Array Express database at the European Bioinformatics Institute (EBI). Accession codes are reported in Supplementary   Table 1 . Microarray quality checks were performed by analyzing the Relative Log Expression (RLE) and Normalized Unscaled Standard Error (NUSE) scores with the Bioconductor packages affyPLM (Brettschneider et al., 2008) and hgu133plus2hsentrezgcdf (Dai et al., 2005) in the statistical language R (R Development Core Team). The cut-offs for defining high quality were set as (1 st quartile -[1.5 ´ interquartile range]) and (3 rd quartile + [1.5 ´ interquartile range]).
All microarrays were pre-processed (normalized) simultaneously in R with the Robust Multichip Average (RMA) algorithm (Irizarry et al., 2003) including background adjustment, quantile normalization and summarization using custom brainarray Chip Description Files (CDF; ENTREZG, v19) yielding one optimized probe-set per gene (Dai et al., 2005) .
Identification of CSG-scores from normalized expression intensities
To identify CSGs in any given gene expression dataset, we calculated the outlier expression of a gene x in a specific cancer c by considering the adjusted upper quartile mean of its expression signals, as such approach avoids bias through extreme outliers in a tiny subset of samples (above 95 th quantile [Q95]) (Xu et al., 2012) . The adjusted upper quartile mean, named 'Outlier Score' (OS), of gene x in cancer type c is given as ( , ) = log (Mean 75, 95 ; 2).
Next, a 'Penalty Score' (PS) for gene x was calculated on the basis of its adjusted upper quartile mean among different types of normal human tissues n as , = [ ( 75, 95); 2 .
The CSG-score of a gene x in a given cancer type c was then calculated as , = ( , ) − ( , ).
Previously reported algorithms included weighting scores for each normal tissue type based on their possible degree of estimated 'immuno-privilege' or even excluded highly immuneprivileged organs such as testis from calculation of a PS (Kadota et al., 2006; Xu et al., 2012) .
In contrast, we considered each normal tissue type including testis as equally relevant for calculating the PS of a given gene, as otherwise our list of CSGs would be exceedingly enriched in established cancer-testis antigens. However, as gender-specific normal tissue types such as uterus/ovary or prostate/testis, respectively, are irrelevant to nominate CSGs for the respective other gender, we calculated gender-specific CSG-scores omitting genderspecific tissue types for calculation of the PS of a given gene for the respective other gender ( Supplementary Table 1 ). A meaningful CSG-score was determined statistically as being equal or above the 99.9 th percentile of all CSG-scores calculated across all cancer entities.
Using this cut-off, the CSG-scores for CSGs potentially suitable for immunotherapeutic targets in a given cancer entity were usually greater than 2. CSG-scores greater than 3 were empirically considered as high and those greater than 4 as very high.
Development of RAVEN (Rich Analysis of Variable gene Expressions in Numerous tissues)
We developed an application named RAVEN that incorporates several statistical methods to easily identify putative highly immunogenic peptides encoded by CSGs from any gene expression dataset. RAVEN and a detailed handbook as well as associated datasets can be Nielsen, 2016; Nielsen et al., 2003) . The peptide search service (Chen et al., 2013) of UniProt is queried via a RESTful web service which API is provided and integrated by Protein Information Resource (PIR) using ApacheLucene for peptide text searches (Chen et al., 2013; Wu et al., 2003) . In RAVEN, this approach is available for the most common alleles in human and mouse. In contrast to other methods provided by RAVEN, this pipeline is independent from the analyzed gene expression dataset but requires an internet connection.
Human cell lines and cell culture conditions
Cells were grown at 37°C in humidified 5% CO 2 atmosphere in RPMI 1640 medium (Biochrom, Berlin, Germany) supplemented with 10% FCS (Biochrom) and 100 U/ml penicillin and 100 µg/ml streptomycin (Biochrom). TAP-deficient HLA*A02:01 + T2 cell line (somatic cell hybrid) was obtained from P. Cresswell (Yale University School of Medicine, New Haven, CT, USA). T2 cells were maintained in RPMI 1640 medium additionally supplemented with 1 mM sodium pyruvate and non-essential amino acids (both Biochrom).
Cell line purity was confirmed by short tandem repeat profiling (latest profiling 15 th December 2015) and cells were routinely examined by PCR for the absence of mycoplasma.
A list of the used cell lines is provided in Supplementary Table 2 .
RNA extraction, reverse transcription and qRT-PCR
RNA was extracted with the Nucleospin RNA kit (Macherey-Nagel, Düren, Germany) containing a 15 min on-column DNA digestion step to degrade genomic DNA. RNA was reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCRs were performed using SYBR Select Master Mix (Applied Biosystems). Oligonucleotides were purchased from MWG Eurofins Genomics (Ebersberg, Germany). Primer sequences are listed in Supplementary Table 3 . Reactions were run in 10-20 µl final volume on a CFX Connect instrument and analyzed using the CFX Manager 3.1 (both Bio-Rad). Gene expression levels of specific genes were normalized to that of the housekeeping gene RPLP0 (Martin, 2016) . At least three high-power fields (40x) of each core for every sample were assessed. Semiquantitative evaluation of immunoreactivity was carried out by two independent physicians trained in histopathology. The intensity of immunoreactivity was determined as grade 0 = none, grade 1 = faint, grade 2 = moderate and grade 3 = strong. The particular percentage score of cells was assigned to 0, when any immunoreactivity was present in less than 20% of the cells, 20-39% to 1, 40-59% to 2, 60-79% to 3 and 80% or higher to 4. For calculation of overall immunoreactivity for the given protein, we multiplied the intensity score with the percentage score, in analogy to UICC guidelines for hormone receptor scoring in human breast cancer as described (Remmele and Stegner, 1987) .
Human samples and ethics approval
Peptide binding assay using TAP deficient T2 cells
All peptides were solid-state synthesized with the highly-parallelized LIPS ® technology (Elephants & Peptides, Potsdam, Germany). As a positive control, we used an established highly affine influenza matrix protein epitope (M158-66; sequence GILGFVFTL) (Gotch et al., 1987) . 
RESULTS
Dataset assembly, workflow, and basic concepts of RAVEN
In order to automatize the systematic and fast identification of CSGs as well as the prediction of corresponding highly affine peptides for any given MHC, we developed a user-friendly software named RAVEN (Rich Analysis of Variable gene Expressions in Numerous tissues).
An overview on the workflow conducted by RAVEN is given in Fig. 1 . The software, a detailed user guide and our gene expression datasets are freely available under https://github.com/JSGerke/RAVENsoftware.
Transcriptome-wide detection of CSGs overexpressed in multiple cancer entities with
RAVEN
Previous studies have shown that many established CSGs are only expressed in subsets of specific cancer entities, which is often referred to as 'outlier' expression (Wu, 2007; Xu et al., 2012) . Indeed, many CSGs are either virtually not expressed in somatic normal tissues or exclusively expressed in specific lineages such as embryonal and germline tissues (Monk and Holding, 2001; Simpson et al., 2005) . This outlier expression discriminates cancer cells from normal somatic cells and may offer a therapeutic window for preferentially targeting cancer cells, e.g. by adoptive T cell therapy (Coulie et al., 2014) . Also, it may increase the likelihood that lymphocytes responsive to the proteins encoded by CSGs are preserved in the mature lymphocyte repertoire (Simpson et al., 2005) , because they are not counter-selected during lymphocyte development. However, an outlier expression profile implies that conventional statistical tests, which either simply aim at identifying generally upregulated CSGs across many cancer samples (e.g. Student's t-test) or ignore the strength of overexpression in a small subset of patients (e.g. rank-based nonparametric tests), would fail to detect such clinically relevant CSGs.
Therefore, we developed a scoring algorithm to scan transcriptome-wide for CSGs by assigning an 'outlier score' (OS) to each gene for high expression in a given cancer entity, which is penalized by a 'penalty score' (PS) if high expression in any normal tissue type is present.
Both scores are calculated for each gene separately as the mean expression level of the 95 th and 75 th percentile. Then, we calculated an overall score for each gene named 'CSG-score', which is built by subtracting the gene-specific PS from the OS. This function highlights all genes overexpressed in only a subset of cancer samples, while avoiding the misrepresentation caused by extremely high outlier expression signals in single samples.
In addition, our algorithm takes into account gender-specific normal tissue types such as uterus and prostate. Specifically, our algorithm calculated gender-specific CSG-scores for each gene excluding normal tissues of sexual organs specific for the other gender (see
Materials and Methods).
To analyze the expression profiles of human genes in normal and cancer tissues we compiled 85 Affymetrix HG-U133-Plus2.0 microarray datasets for 71 normal tissues and 50 cancer types with a focus on oligo-mutated pediatric cancers and sarcomas, totaling to 2701 highquality and simultaneously normalized samples ( Supplementary Table 1 ). In prospect of a future exploitation of our CSGs as clinical immunotargets, we included graft versus host disease (GvHD)-sensitive normal tissue types such as retina and colonic mucosa as well as normal B and T cells to obviate fratricide effects, which can compromise adoptive T cell therapies Leisegang et al., 2010) .
Applying our scoring algorithm to this well-curated gene expression dataset, RAVEN identified 806 non-redundant CSGs (defined by a CSG-score above the 99.9 th percentile of all scores across 50 cancer entities) ( Fig. 2, Supplementary Table 5 ). Among them we found not only many established CSGs such as LIPI for Ewing sarcoma (Foell et al., 2008) , PRAME for neuroblastoma (Oberthuer et al., 2004; Spel et al., 2015) and members of the MAGE-family for germinoma (Hara et al., 1999) , neuroblastoma (Söling et al., 1999) , synovial sarcoma (Iura et al., 2017) , multiple myeloma (Condomines et al., 2007) , diffuse large B cell lymphoma (DLBCL) (Hudolin et al., 2013) , and osteosarcoma (Sudo et al., 1997) , but also many novel candidates of which some appear to be suitable for targeting multiple cancer entities (Fig. 2, Supplementary Table 5) .
The specific expression of nine selected CSGs was confirmed by qRT-PCR in a panel of cancer cell lines from six different tumor entities. As shown in Fig. 3A , there was a high concordance of calculated CSG-scores and expression intensities measured by microarrays in primary tumors with relative mRNA expression levels measured by qRT-PCR in corresponding cancer-derived cell lines.
In particular, PAX7 (paired box 7) showed a very high CSG-score (>5) in multiple cancer entities including oligo-mutated Ewing sarcoma. Therefore, we validated its strong overexpression on protein level in a subset of these cancer entities by immunohistochemistry in a comprehensive tissue microarray (TMA, n = 412 samples) also containing somatic and germline normal tissue types. As shown in Fig. 3B,C, PAX7 was exclusively expressed in cancer entities with high CSG-scores, while being virtually not expressed in normal tissues.
Collectively, these data demonstrate that RAVEN can reliably identify CSGs with specific overexpression in multiple cancers as compared to normal tissues.
Prediction of non-redundant CSG-encoded peptides with high MHC-affinity by RAVEN
To identify peptides encoded by CSGs suitable for a targeted immunotherapy, we implemented the artificial neural network (ANN) algorithm (Andreatta and Nielsen, 2016; Nielsen et al., 2003) provided by the immune epitope database IEDB 3.0 (Vita et al., 2015) .
RAVEN can apply this ANN algorithm to predict peptide-affinities for different peptide lengths and the most common human and murine MHC-subtypes.
In our list of 806 CSGs, RAVEN predicted potential highly affine peptides for 9-mers, which usually show optimal binding to most MHC class I molecules (Andreatta and Nielsen, 2016; Eichmann et al., 2014) , and for HLA-A02:01, which is the most common MHC-I in Caucasians (González-Galarza et al., 2015) . RAVEN automatically crosschecked these peptides by a text search algorithm with ApacheLucene (Chen et al., 2013; Wu et al., 2003) against the human reference-proteome (UniProt release 2015_06) to exclude sequence identity with non-specifically expressed proteins. In total, RAVEN predicted 7,338 9-mer peptides with high MHC-I-affinity (defined as a dissociation constant K d ≤ 150 nM) of which 6,554 had no sequence identity with any other protein ( Supplementary Table 6 ).
Predicted CSG-encoded peptides exhibit strong affinity to MHCs
We next sought to confirm the predicted affinity of peptides to human HLA-A02:01 proposed by RAVEN. Therefore, we selected among the unique 6,554 peptides 80, which covered all 50 analyzed tumor entities and which had high to very high CSG-scores. For these 80 peptides, we designed a customized solid-phase synthesized peptide-library and assessed whether they can stabilize MHC-I on the surface of TAP2-deficient cells in T2-binding assays. As shown in Figure 4A , 38 of 80 tested peptides (47.5%) achieved at least 50% of the MHC-stabilizing effect of a highly immunogenic influenza control peptide (GILGFVFTL, Supplementary Table 6 ) at a saturation dose of 100 µM. For these CSG-peptides, we repeated the T2-assays with six different peptide concentrations (0.1 to 100 µM). Strikingly, some of them, including the one encoded by PAX7, showed MHC-stabilization kinetics similar to the influenza peptide (Figure 4B) . Taken together, these experiments demonstrated that RAVEN can identify highly affine CSG-encoded peptides suitable for targeting multiple cancer types by leveraging publicly available gene expression data.
DISCUSSION
High-throughput gene expression analyses of cancers and normal tissues generated comprehensive and freely available transcriptome datasets (Rung and Brazma, 2013) .
However, identification of CSGs and derivative peptides with high affinity to MHCs continued to be laborious and slow (Gubin et al., 2015) .
Here, we reported on the development and application of a mathematical scheme for transcriptome-wide detection of CSGs and their corresponding highly MHC-affine peptides as immunologic and clinical targets, and provide a use-friendly software (RAVEN), which automatizes this process. Applying RAVEN to a large gene expression dataset comprising multiple and often oligo-mutated pediatric cancer types as well as a broad spectrum of normal tissues revealed many CSGs with diagnostic and therapeutic potential. Moreover, we provide an analogous dataset including 19 of the most common carcinoma entities (1,462 samples; Supplementary Table 1 , https://github.com/JSGerke/RAVENsoftware), which can be used for CSG identification in these tumor types.
In our pediatric cancer dataset, we observed significant enrichment (P < 0.0001, Chi 2 -test) of established cancer-testis antigens (CTDatabase, www.cta.lncc.br, (Almeida et al., 2009) ), but also identified many novel candidates including PAX7. PAX7 encodes a paired box transcription factor required for embryonal neural development (Kawakami et al., 1997) and renewal of skeletal muscle stem cells (Oustanina et al., 2004) . Translocations involving PAX7
and FKHR are found in the majority of alveolar rhabdomyosarcomas (ARMS), indicating a role of PAX7 in the pathogenesis of myogenic tumors (Barr, 1999) . Using RAVEN, we identified PAX7 as a strong CSG in multiple oligo-mutated cancer entities such as Ewing sarcoma, Ewing-like sarcomas with a BCOR-CCNB3-translocation and embryonal as well as alveolar fusion-negative rhabdomyosarcoma. Its exclusive expression in these cancer entities was confirmed on protein level by IHC. Strikingly, PAX7 encodes a 9-mer peptide (GLVSSISRV) with very high affinity for the most frequent MHC-I subtype in Caucasians (HLA-A02:01) (González-Galarza et al., 2015) , rendering PAX7 as an attractive target for immunotherapy for multiple oligo-mutated cancers.
The parameters of the analysis applied in RAVEN have been optimized to discover CSGs, which are virtually not expressed in most somatic tissues. Although some identified CSGs did not encode peptides suitable for immunotargets, a subset of them could constitute interesting targets for conventional pharmacotherapy. In fact, the CSGs FGFR4, CDK4, and several
MMPs, which are specifically overexpressed in rhabdomyosarcoma (FGFR4), liposarcoma (CDK4), and desmoid tumors, leiomyoma, osteosarcoma and adamantinomatous craniopharyngioma (MMPs) ( Supplementary Table 5 ), respectively, could be targeted by specific inhibitors currently in clinical trials (Chen et al., 2017; Hagel et al., 2015; Matziari et al., 2007) .
Besides their potential utility as (immune)-therapeutic targets, some CSGs may harbor the potential to serve as diagnostic markers: While CSGs expressed in multiple tumor entities could be utilized for cancer-screening, CSGs exclusively expressed in certain cancer types can be used to identify and differentiate specific tumor entities. This could be important for determining treatment options, which is often difficult in cancers of unknown primary.
As RAVEN can also be applied to datasets only containing cancer samples, RAVEN can easily identify potential diagnostic markers among several cancers in parallel. In principle, our work-flow embedded in RAVEN provides an unbiased approach for transcriptome-wide detection of CSGs, which can be adapted to many specific applications, such as the identification of autoantibody signatures, biomarkers, tumor vaccine targets, or membrane antigen targets. Its performance could be further enhanced by combining it with other datasets, on cancer plasma or membrane proteomics. Since our algorithm provides a quantitative and gender-specific value for each gene in each tumor entity (Supplementary Relative gene expression intensities of the top-5 CSGs for each cancer entity excluding overlapping CSGs with other tumor entities re indicated in greyscale with black color representing high and white color low expression. Each line represents an individual CSG (for a complete list see Supplementary Table 5) ; each column represents one primary tumor/leukemia sample. The bar graph on the right displays the number of different cancer entities in which the corresponding CSG reached a CSG-score above the 99.9 th percentile of all CSG-scores. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid/rhabdoid tumor; CLL, chronic lymphatic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B cell lymphoma; GIST, gastrointestinal stromal tumor; MALT, mucosa associated lymphatic tissue; MPNST, malignant peripheral nerve sheath tumor; PNET, primitive neuroectodermal tumor. A) Relative MHC-I-affinity of 80 selected peptides at 100 µM in T2-binding assays as compared to a highly affine influenza peptide (peptide sequences are given in Supplementary Table 6 ). The colored boxes at the right side of the graph represent the number and type of cancer entities in which the corresponding CSG encoding the indicated peptide is overexpressed. Peptides with a MHC-affinity of ≥ 50% of the influenza peptide are highlighted in red color. Data are presented as mean and SEM of n ≥ 3 experiments. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid/rhabdoid tumor; CLL, chronic lymphatic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B cell lymphoma; GIST, gastrointestinal stromal tumor; MALT, mucosa associated lymphatic tissue; MPNST, malignant peripheral nerve sheath tumor; PNET, primitive neuroectodermal tumor. B) Normalized fluorescence signals of 16 selected peptides with high MHC-affinity as compared to that of a highly affine influenza peptide in T2-binding assays. Data are presented as mean and SEM of n ≥ 3 experiments. P values of a Spearman's rank-order correlation are reported.
